Skip to content

Development of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People

Development of a New Device and Method for Determining Refractive Errors in a Myopic Population

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07297810
Acronym
MDSW_DiVA2Rx
Enrollment
30
Registered
2025-12-22
Start date
2025-12-31
Completion date
2027-09-30
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

The purpose of this clinical investigation is to check whether the new device can correctly measure a person's degree of myopia and astigmatism. To evaluate and improve the device's performance, the results (optical correction values and the associated visual acuity) obtained with the investigational device will be compared with the results obtained using standard instruments commonly used by eye care professionals.

Interventions

DEVICEOptical correction values obtained with investigational device and visual acuity

Participants optical correction values are determined using the investigational device and their visual acuity is measured with this optical correction

DEVICEOptical correction values obtained with an autorefractometer and visual acuity

Participants optical correction values are determined using an autorefractometer (objective refraction) and their visual acuity is measured with this optical correction

DEVICEOptical correction values obtained with a phoropter and visual acuity

Participants optical correction values are determined using a phoropter (subjective refraction) and their visual acuity is measured with this optical correction

Sponsors

Essilor International
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* Volunteers, fluent in French, willing to follow the protocol, able to read and understand the information form and give free and informed consent * Aged between 18 and 39 years at the time of study inclusion * Wear corrective glasses * With an ophthalmologist's prescription for corrective eyewear less than 3 years old * Spherical error of each meridian within the range of \[-5.00 ; -0.50 D\] * Cylindrical defect included in interval \[-4.50 ; 0.00 D\] * Corrected monocular visual acuity ≤ 0.0 logMAR for distance vision (≥10/10) * French Social Security beneficiary

Exclusion criteria

General criteria for non-inclusion: * Essilor International employee * Pregnant, or breast-feeding women (Article L1121-5) * Persons deprived of their liberty by a judicial or administrative decision and persons hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and persons admitted to a health or social establishment for purposes other than research * Adults incapable or unable to express consent (Article L1121-8) * Participant included in another ongoing study or in a period of exclusion * All categories of persons particularly protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the French Public Health Code) * Amblyopia, strabismus, nystagmus * Wearing progressive lenses The following elements are considered based on the participant's declaration : * Declared cataract, Aphakia (without lens) or pseudophakia (with intraocular implant) * Ocular surgery (iridectomy, refractive surgery, corneal transplant) * Ocular trauma (corneal deformation, contusion, chemical burn, foreign body intrusion, perforation, orbital fracture, enucleation) * Severe ocular pathology, involving loss of visual field as in glaucoma or retinitis pigmentosa, involving loss of acuity and severe discomfort in dimly or brightly lit environments as in Age related macular degeneration (AMD) or overt and treated dry eye. * Systemic pathology affecting vision (diabetes, uncontrolled blood pressure, myasthenia gravis, etc.). * Medication that may affect vision or interfere with study measures (antidepressants, medication with atropine-like effects). * Declared neurological deficits, in particular a history of epileptic pathology or sensory-motor coordination disorders, vestibular or cerebellar pathology (e.g. balance disorders).

Design outcomes

Primary

MeasureTime frameDescription
Difference of Optical ValuesDay OneOptical correction values obtained with the investigational device are compared with the values obtained using a phoropter (gold standard method - subjective refraction)
Difference in the proportion of visual acuity levelsDay OneComparison of the proportion of participants reaching specific monocular visual acuity levels (≥10/10 and ≥12/10) when wearing the refraction obtained from the investigational device versus the subjective refraction obtained from a phoropter (gold standard method)

Secondary

MeasureTime frameDescription
Comparison of Monocular Visual Acuity DistributionDay OneComparison of the distribution of monocular visual acuity obtained using the refraction from the investigational device versus the objective refraction from an autorefractometer.

Countries

France

Contacts

Primary ContactStéphane Boutinon, Master of engineering
boutinos@essilor.fr+33 6 77 16 43 83

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026